A Survival God for the Age of Abundance,” Peter H. Diamandis and Steven Kotler explore what it means to be human in a world ...

The Australian oncology drug developer named Rao to lead research and development for its cancer therapy pipeline.

Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high ...

Endogenous Retroviruses (ERVs), relics from ancient viral infections, form a significant part of vertebrate genomes, including humans, where they constitute ...

Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute. Brisbane-based QIMR Berghofer develop ...

Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in ...

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

ER-100 is being tested to restore vision by resetting the biological age of eye cells through epigenetic reprogramming, ...

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create “transcriptional addiction” in cancer. They function via ...

Before a child speaks a first word or misses a developmental milestone, clues about autism and ADHD risk may already be ...